The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Patients must have a Lp(a) value of ≥ 200 nmol/L during screening.
Contact phone
Sparrow Clinical Research Institute | 517.364.5760
Contact email
scri@sparrow.org
Principal investigator
Dr. David Strobl, DO
Trial Category
Heart & Vascular
Trial SubCategory
Cardiovascular Disease
Webform